- Home
- PEPG vs RIGL Comparison
PEPG vs RIGL Comparison
Compare PEPG & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEPG
- RIGL
- Stock Information
- Founded
- PEPG 2018
- RIGL 1996
- Country
- PEPG United States
- RIGL United States
- Employees
- PEPG N/A
- RIGL N/A
- Industry
- PEPG Biotechnology: Pharmaceutical Preparations
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PEPG Health Care
- RIGL Health Care
- Exchange
- PEPG Nasdaq
- RIGL Nasdaq
- Market Cap
- PEPG 250.3M
- RIGL 247.1M
- IPO Year
- PEPG 2022
- RIGL 2000
- Fundamental
- Price
- PEPG $4.32
- RIGL $25.04
- Analyst Decision
- PEPG Buy
- RIGL Buy
- Analyst Count
- PEPG 3
- RIGL 5
- Target Price
- PEPG $14.67
- RIGL $31.30
- AVG Volume (30 Days)
- PEPG 133.3K
- RIGL 288.9K
- Earning Date
- PEPG 11-07-2024
- RIGL 11-07-2024
- Dividend Yield
- PEPG N/A
- RIGL N/A
- EPS Growth
- PEPG N/A
- RIGL N/A
- EPS
- PEPG N/A
- RIGL 0.22
- Revenue
- PEPG N/A
- RIGL $157,374,000.00
- Revenue This Year
- PEPG N/A
- RIGL $38.26
- Revenue Next Year
- PEPG N/A
- RIGL $24.21
- P/E Ratio
- PEPG N/A
- RIGL $109.79
- Revenue Growth
- PEPG N/A
- RIGL 21.65
- 52 Week Low
- PEPG $4.00
- RIGL $7.48
- 52 Week High
- PEPG $19.30
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- PEPG 23.52
- RIGL 68.80
- Support Level
- PEPG $4.00
- RIGL $22.33
- Resistance Level
- PEPG $4.77
- RIGL $29.16
- Average True Range (ATR)
- PEPG 0.56
- RIGL 2.30
- MACD
- PEPG -0.05
- RIGL 0.41
- Stochastic Oscillator
- PEPG 9.14
- RIGL 69.96
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.